| 1 |
Torosian K, Lal E, Kavanaugh A, Loomba R, Ajmera V, Guma M. Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Semin Arthritis Rheum 2023;59:152165. [PMID: 36716599 DOI: 10.1016/j.semarthrit.2023.152165] [Reference Citation Analysis]
|
| 2 |
Wang X, Guo W, Shi X, Chen Y, Yu Y, Du B, Tan M, Tong L, Wang A, Yin X, Guo J, Martin RC, Bai O, Li Y. S1PR1/S1PR3-YAP signaling and S1P-ALOX15 signaling contribute to an aggressive behavior in obesity-lymphoma. J Exp Clin Cancer Res 2023;42:3. [PMID: 36600310 DOI: 10.1186/s13046-022-02589-7] [Reference Citation Analysis]
|
| 3 |
Tan H, Yue T, Chen Z, Wu W, Xu S, Weng J. Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. Int J Biol Sci 2023;19:66-88. [PMID: 36594101 DOI: 10.7150/ijbs.73936] [Reference Citation Analysis]
|
| 4 |
Zhen Q, Liang Q, Wang H, Zheng Y, Lu Z, Bian C, Zhao X, Guo X. Theabrownin ameliorates liver inflammation, oxidative stress, and fibrosis in MCD diet-fed C57BL/6J mice. Front Endocrinol (Lausanne) 2023;14:1118925. [PMID: 36742397 DOI: 10.3389/fendo.2023.1118925] [Reference Citation Analysis]
|
| 5 |
Gutiérrez-Cuevas J, Lucano-Landeros S, López-Cifuentes D, Santos A, Armendariz-Borunda J. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. Cancers (Basel) 2022;15. [PMID: 36612019 DOI: 10.3390/cancers15010023] [Reference Citation Analysis]
|
| 6 |
Li Y, Hong YK, Wang X, Pandit H, Zheng Q, Yu Y, Shi X, Chen Y, Tan M, Pulliam Z, Bhutiani N, Lin A, Badach J, Zhang P, Martin RC. Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma. Clin Transl Immunology 2022;11:e1430. [PMID: 36452477 DOI: 10.1002/cti2.1430] [Reference Citation Analysis]
|
| 7 |
Falamarzi K, Malekpour M, Tafti MF, Azarpira N, Behboodi M, Zarei M. The role of FGF21 and its analogs on liver associated diseases. Front Med 2022;9. [DOI: 10.3389/fmed.2022.967375] [Reference Citation Analysis]
|
| 8 |
Yang B, Yang X, Tan X, Lu L, Fan W, Barbier-Torres L, Steggerda J, Liu T, Yang H. Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2022;2022:6799414. [PMID: 36397950 DOI: 10.1155/2022/6799414] [Reference Citation Analysis]
|
| 9 |
Khanmohammadi S, Kuchay MS. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease. Pharmacological Research 2022;185:106507. [DOI: 10.1016/j.phrs.2022.106507] [Reference Citation Analysis]
|
| 10 |
Zhihai Huang, Hung Wen (Kevin) Lin, Quanguang Zhang, Xuemei Zong. Targeting Alzheimer’s Disease: The Critical Crosstalk between the Liver and Brain. Nutrients 2022;14:4298. [PMID: 36296980 DOI: 10.3390/nu14204298] [Reference Citation Analysis]
|
| 11 |
Sui Y, Chen J. Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers. Int J Biol Sci 2022;18:5928-42. [PMID: 36263162 DOI: 10.7150/ijbs.76924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Korkmaz D, Konya P, Demirtürk N. Investigation of the Characteristics of Crimean Congo Hemorrhagic Fever Cases Reported in Afyonkarahisar Province. Turkiye Parazitol Derg 2022;46:224-227. [DOI: 10.4274/tpd.galenos.2022.14633] [Reference Citation Analysis]
|
| 13 |
Yu S, Wang J, Zheng H, Wang R, Johnson N, Li T, Li P, Lin J, Li Y, Yan J, Zhang Y, Zhu Z, Ding X. Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. J Hepatocell Carcinoma 2022;9:855-67. [PMID: 36051860 DOI: 10.2147/JHC.S377768] [Reference Citation Analysis]
|
| 14 |
Liu Y, Liu S, Zhao GS, Li X, Gao F, Ren ZZ, Bian J, Wu JL, Zhang YW. Early changes in peripheral blood cytokine levels after the treatment of metastatic hepatic carcinoma with CalliSpheres microspheres drug-eluting beads transcatheter arterial chemoembolization. Front Oncol 2022;12:889312. [DOI: 10.3389/fonc.2022.889312] [Reference Citation Analysis]
|
| 15 |
Buell-Acosta JD, Garces MF, Parada-Baños AJ, Angel-Muller E, Paez MC, Eslava-Schmalbach J, Escobar-Cordoba F, Caminos-Cepeda SA, Lacunza E, Castaño JP, Nogueiras R, Dieguez C, Ruiz-Parra AI, Caminos JE. Maternal Fibroblast Growth Factor 21 Levels Decrease during Early Pregnancy in Normotensive Pregnant Women but Are Higher in Preeclamptic Women-A Longitudinal Study. Cells 2022;11. [PMID: 35883694 DOI: 10.3390/cells11142251] [Reference Citation Analysis]
|
| 16 |
Zhang C, Liu S, Yang M. The Role of Interferon Regulatory Factors in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Gastroenterology Insights 2022;13:148-61. [DOI: 10.3390/gastroent13020016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Berthou F, Sobolewski C, Abegg D, Fournier M, Maeder C, Dolicka D, Correia de Sousa M, Adibekian A, Foti M. Hepatic PTEN Signaling Regulates Systemic Metabolic Homeostasis through Hepatokines-Mediated Liver-to-Peripheral Organs Crosstalk. IJMS 2022;23:3959. [DOI: 10.3390/ijms23073959] [Reference Citation Analysis]
|
| 18 |
Iacob SA, Iacob DG. Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients – a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown. Front Endocrinol 2022;13:814209. [DOI: 10.3389/fendo.2022.814209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Kim J, Lee S, Lee M. Suppressive Effect of Autocrine FGF21 on Autophagy-Deficient Hepatic Tumorigenesis. Front Oncol 2022;12:832804. [DOI: 10.3389/fonc.2022.832804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Liu ZY, Luo Y, Fang AP, Wusiman M, He TT, Liu XZ, Yishake D, Chen S, Lu XT, Zhang YJ, Zhu HL. High serum fibroblast growth factor 21 is associated with inferior hepatocellular carcinoma survival: A prospective cohort study. Liver Int 2022;42:663-73. [PMID: 34812573 DOI: 10.1111/liv.15100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Sarkar S, Chen S, Spencer B, Situ X, Afkarian M, Matsukuma K, Corwin MT, Wang G. Non-Alcoholic Steatohepatitis Severity Associates with FGF21 Level and Kidney Glucose Uptake. Metab Syndr Relat Disord 2021;19:491-7. [PMID: 34448598 DOI: 10.1089/met.2021.0055] [Reference Citation Analysis]
|
| 22 |
Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells 2021;10:2034. [PMID: 34440803 DOI: 10.3390/cells10082034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 23 |
Siemienowicz KJ, Furmanska K, Filis P, Talia C, Thomas J, Fowler PA, Rae MT, Duncan WC. Pubertal FGF21 deficit is central in the metabolic pathophysiology of an ovine model of polycystic ovary syndrome. Mol Cell Endocrinol 2021;525:111196. [PMID: 33556473 DOI: 10.1016/j.mce.2021.111196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 24 |
Wang Y, Liu D, Zhang T, Xia L. FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. Cancers (Basel) 2021;13:1360. [PMID: 33802841 DOI: 10.3390/cancers13061360] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 25 |
Luo Y, Li X, Ma J, Abbruzzese JL, Lu W. Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity. Cancers (Basel) 2021;13:778. [PMID: 33668583 DOI: 10.3390/cancers13040778] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 26 |
Talukdar S, Kharitonenkov A. FGF19 and FGF21: In NASH we trust. Mol Metab 2021;46:101152. [PMID: 33383173 DOI: 10.1016/j.molmet.2020.101152] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 27 |
Carneros D, López-Lluch G, Bustos M. Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E3472. [PMID: 33198247 DOI: 10.3390/nu12113472] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
